Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway

Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression

(2018) Linda Xiaoyan Li et al.   Cell Death & Disease

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer

(2017) C Hardin et al.   EXPERT OPINION ON PHARMACOTHERAPY

Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease

(2017) Linda Xiaoyan Li et al.   JOURNAL OF CLINICAL INVESTIGATION

Lung cancer: current therapies and new targeted treatments

(2017) Fred R Hirsch et al.   LANCET

Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity

(2017) Lihui Wang et al.   Cell Death & Disease

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus–unrelated nonmultiple head and neck carcinomas

(2016) Rie Ohtomo-Oda et al.   HUMAN PATHOLOGY

Lysine methylation represses p53 activity in teratocarcinoma cancer cells

(2016) Jiajun Zhu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Emerging roles of lysine methylation on non-histone proteins

(2015) Xi Zhang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Lysine methyltransferase Smyd2 suppresses p53-dependent cardiomyocyte apoptosis

(2014) Amna Sajjad et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Overexpression of SMYD2 contributes to malignant outcome in gastric cancer

(2014) S Komatsu et al.   BRITISH JOURNAL OF CANCER

SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation

(2014) Ryuji Hamamoto et al.   CANCER LETTERS

Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer

(2014) Sheila Piva et al.   CURRENT PHARMACEUTICAL DESIGN

SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor

(2014) Luis Henrique Toshihiro Sakamoto et al.   LEUKEMIA RESEARCH

Systems biology of cisplatin resistance: past, present and future

(2014) L Galluzzi et al.   Cell Death & Disease

HtrA1 Downregulation Induces Cisplatin Resistance in Lung Adenocarcinoma by Promoting Cancer Stem Cell-Like Properties

(2013) Yongqing Xu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Structural Basis of Substrate Methylation and Inhibition of SMYD2

(2011) Andrew D. Ferguson et al.   STRUCTURE

Use of molecular markers for predicting therapy response in cancer patients

(2010) Michael J. Duffy et al.   CANCER TREATMENT REVIEWS

Methylation of the Retinoblastoma Tumor Suppressor by SMYD2

(2010) Louis A. Saddic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

(2010) Alex Chang   LUNG CANCER